Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates

分组1 - Caribou Biosciences reported a quarterly loss of $0.28 per share, better than the Zacks Consensus Estimate of a loss of $0.33, and improved from a loss of $0.39 per share a year ago, resulting in an earnings surprise of +14.11% [1] - The company achieved revenues of $3.94 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 56.02%, and up from $2.08 million in the same quarter last year [2] - Caribou Biosciences has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] 分组2 - The stock has gained approximately 13.2% since the beginning of the year, significantly outperforming the S&P 500, which gained only 0.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.36 on revenues of $2.5 million, and for the current fiscal year, it is -$1.44 on revenues of $32.43 million [7] - The Medical - Biomedical and Genetics industry, to which Caribou Biosciences belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, indicating potential challenges ahead [8]